Document is current
Any future updates will be listed below
-
Authors
Ekenbäck, Christina https://orcid.org/0000-0002-4401-7117
Persson, Jonas
Tornvall, Per
Forsberg, Lena
Spaak, Jonas
-
Funding
Funding for this research was provided by:
Hjärt-Lungfonden (20160775, 20160782, 20190535, 20200797)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 27 June 2024
Accepted: 29 October 2024
First Online: 15 November 2024
Declarations
:
: Christina Ekenbäck has received minor speaker honoraria from Medtronic and Orion Pharma. Jonas Persson has received unrestricted grants from Abbott Inc. Jonas Spaak has received speaker honoraria from AstraZeneca, Sanofi, Boehringer Ingelheim, Novo Nordisk and Bayer, and is a minor shareholder of Beat Vascular Health AB, all outside the present work. Per Tornvall and Lena Forsberg have no relevant financial or non-financial interests to disclose.
: This study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice, approved by the Stockholm Regional Board of Ethics (2014/1856–31) and supplemented with approval from the Swedish Ethical Review Authority (2020–05104). The study is registered at ClinicalTrials.gov (NCT05768542). All participants provided written informed consent prior to inclusion in the study.
